Results 131 to 140 of about 410,734 (218)
Paediatric clonidine medication errors: Findings from a multicentre French study
Aims This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years ...
Eve‐Marie Thillard +8 more
wiley +1 more source
Lactate-driven histone lactylation by AARS1 promotes pulmonary arterial hypertension. [PDF]
Chen Z +8 more
europepmc +1 more source
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza +12 more
wiley +1 more source
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou +10 more
wiley +1 more source
Frailty in Pulmonary Arterial Hypertension: A Cohort Study. [PDF]
Farley GJ +8 more
europepmc +1 more source
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said +13 more
wiley +1 more source
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
WCN25-4438 JC VIRUS IS UNDERESTIMATED IN KIDNEY TRANSPLANT RECIPIENTS
Mirha Pjanic +6 more
doaj +1 more source
CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien +7 more
wiley +1 more source
Endothelial Redox Dysregulation in Pulmonary Arterial Hypertension: Compartmentalized Mechanisms and Therapeutic Implications. [PDF]
Moreno-Caceres S, Marciano DP.
europepmc +1 more source

